Targeting Cancer Stem Cells for Treatment of Glioblastoma Multiforme
Cancer stem cells (CSCs) in glioblastoma multiforme (GBM) are radioresistant and chemoresistant, which eventually results in tumor recurrence. Targeting CSCs for treatment is the most crucial issue. There are five methods for targeting the CSCs of GBM. One is to develop a new chemotherapeutic agent...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2013-04-01
|
| Series: | Cell Transplantation |
| Online Access: | https://doi.org/10.3727/096368912X655136 |
| _version_ | 1811210982150635520 |
|---|---|
| author | Der-Yang Cho Shinn-Zong Lin Wen-Kuang Yang M.D., Ph.D. Han-Chung Lee Den-Mei Hsu Hung-Lin Lin Chun-Chung Chen Chun-Lin Liu Wen-Yuan Lee Li-Hui Ho |
| author_facet | Der-Yang Cho Shinn-Zong Lin Wen-Kuang Yang M.D., Ph.D. Han-Chung Lee Den-Mei Hsu Hung-Lin Lin Chun-Chung Chen Chun-Lin Liu Wen-Yuan Lee Li-Hui Ho |
| author_sort | Der-Yang Cho |
| collection | DOAJ |
| description | Cancer stem cells (CSCs) in glioblastoma multiforme (GBM) are radioresistant and chemoresistant, which eventually results in tumor recurrence. Targeting CSCs for treatment is the most crucial issue. There are five methods for targeting the CSCs of GBM. One is to develop a new chemotherapeutic agent specific to CSCs. A second is to use a radiosensitizer to enhance the radiotherapy effect on CSCs. A third is to use immune cells to attack the CSCs. In a fourth method, an agent is used to promote CSCs to differentiate into normal cells. Finally, ongoing gene therapy may be helpful. New therapeutic agents for targeting a signal pathway, such as epidermal growth factor (EGF) and vascular epidermal growth factor (VEGF) or protein kinase inhibitors, have been used for GBM but for CSCs the effects still require further evaluation. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as cyclooxygenase-2 (Cox-2) inhibitors have proven to be effective for increasing radiation sensitivity of CSCs in culture. Autologous dendritic cells (DCs) are one of the promising immunotherapeutic agents in clinical trials and may provide another innovative method for eradication of CSCs. Bone-morphogenetic protein 4 (BMP4) is an agent used to induce CSCs to differentiate into normal glial cells. Research on gene therapy by viral vector is also being carried out in clinical trials. Targeting CSCs by eliminating the GBM tumor may provide an innovative way to reduce tumor recurrence by providing a synergistic effect with conventional treatment. The combination of conventional surgery, chemotherapy, and radiotherapy with stem cell-orientated therapy may provide a new promising treatment for reducing GBM recurrence and improving the survival rate. |
| first_indexed | 2024-04-12T05:05:16Z |
| format | Article |
| id | doaj.art-cad41aa1c56940f88501fc1afbd28d57 |
| institution | Directory Open Access Journal |
| issn | 0963-6897 1555-3892 |
| language | English |
| last_indexed | 2024-04-12T05:05:16Z |
| publishDate | 2013-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cell Transplantation |
| spelling | doaj.art-cad41aa1c56940f88501fc1afbd28d572022-12-22T03:46:53ZengSAGE PublishingCell Transplantation0963-68971555-38922013-04-012210.3727/096368912X655136Targeting Cancer Stem Cells for Treatment of Glioblastoma MultiformeDer-Yang Cho0Shinn-Zong Lin1Wen-Kuang Yang M.D., Ph.D.2Han-Chung Lee3Den-Mei Hsu4Hung-Lin Lin5Chun-Chung Chen6Chun-Lin Liu7Wen-Yuan Lee8Li-Hui Ho9Graduate Institute of Immunology, China Medical University, Taichung, Taiwan, ROCDepartment of Neurosurgery, China Medical University Beigan Hospital, Yunlin, Taiwan, ROCDepartment of Medicine, China Medical University, Taichung, Taiwan, ROCDepartment of Medicine, China Medical University, Taichung, Taiwan, ROCCell/Gene Therapy Research Laboratory, China Medical University Hospital, Taichung, Taiwan, ROCDepartment of Neurosurgery, Neuropsychiatry Center, China Medical University Hospital, Taichung, Taiwan, ROCDepartment of Medicine, China Medical University, Taichung, Taiwan, ROCDepartment of Neurosurgery, Neuropsychiatry Center, China Medical University Hospital, Taichung, Taiwan, ROCDepartment of Medicine, China Medical University, Taichung, Taiwan, ROCDepartment of Neurosurgery, Neuropsychiatry Center, China Medical University Hospital, Taichung, Taiwan, ROCCancer stem cells (CSCs) in glioblastoma multiforme (GBM) are radioresistant and chemoresistant, which eventually results in tumor recurrence. Targeting CSCs for treatment is the most crucial issue. There are five methods for targeting the CSCs of GBM. One is to develop a new chemotherapeutic agent specific to CSCs. A second is to use a radiosensitizer to enhance the radiotherapy effect on CSCs. A third is to use immune cells to attack the CSCs. In a fourth method, an agent is used to promote CSCs to differentiate into normal cells. Finally, ongoing gene therapy may be helpful. New therapeutic agents for targeting a signal pathway, such as epidermal growth factor (EGF) and vascular epidermal growth factor (VEGF) or protein kinase inhibitors, have been used for GBM but for CSCs the effects still require further evaluation. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as cyclooxygenase-2 (Cox-2) inhibitors have proven to be effective for increasing radiation sensitivity of CSCs in culture. Autologous dendritic cells (DCs) are one of the promising immunotherapeutic agents in clinical trials and may provide another innovative method for eradication of CSCs. Bone-morphogenetic protein 4 (BMP4) is an agent used to induce CSCs to differentiate into normal glial cells. Research on gene therapy by viral vector is also being carried out in clinical trials. Targeting CSCs by eliminating the GBM tumor may provide an innovative way to reduce tumor recurrence by providing a synergistic effect with conventional treatment. The combination of conventional surgery, chemotherapy, and radiotherapy with stem cell-orientated therapy may provide a new promising treatment for reducing GBM recurrence and improving the survival rate.https://doi.org/10.3727/096368912X655136 |
| spellingShingle | Der-Yang Cho Shinn-Zong Lin Wen-Kuang Yang M.D., Ph.D. Han-Chung Lee Den-Mei Hsu Hung-Lin Lin Chun-Chung Chen Chun-Lin Liu Wen-Yuan Lee Li-Hui Ho Targeting Cancer Stem Cells for Treatment of Glioblastoma Multiforme Cell Transplantation |
| title | Targeting Cancer Stem Cells for Treatment of Glioblastoma Multiforme |
| title_full | Targeting Cancer Stem Cells for Treatment of Glioblastoma Multiforme |
| title_fullStr | Targeting Cancer Stem Cells for Treatment of Glioblastoma Multiforme |
| title_full_unstemmed | Targeting Cancer Stem Cells for Treatment of Glioblastoma Multiforme |
| title_short | Targeting Cancer Stem Cells for Treatment of Glioblastoma Multiforme |
| title_sort | targeting cancer stem cells for treatment of glioblastoma multiforme |
| url | https://doi.org/10.3727/096368912X655136 |
| work_keys_str_mv | AT deryangcho targetingcancerstemcellsfortreatmentofglioblastomamultiforme AT shinnzonglin targetingcancerstemcellsfortreatmentofglioblastomamultiforme AT wenkuangyangmdphd targetingcancerstemcellsfortreatmentofglioblastomamultiforme AT hanchunglee targetingcancerstemcellsfortreatmentofglioblastomamultiforme AT denmeihsu targetingcancerstemcellsfortreatmentofglioblastomamultiforme AT hunglinlin targetingcancerstemcellsfortreatmentofglioblastomamultiforme AT chunchungchen targetingcancerstemcellsfortreatmentofglioblastomamultiforme AT chunlinliu targetingcancerstemcellsfortreatmentofglioblastomamultiforme AT wenyuanlee targetingcancerstemcellsfortreatmentofglioblastomamultiforme AT lihuiho targetingcancerstemcellsfortreatmentofglioblastomamultiforme |